Phase II window studies: 10 years of experience and counting

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 6, 2001, Pages 334-337

  Smith, Malcolm A ^a   Anderson, Barry ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; HIGH RISK POPULATION; HUMAN; NOTE; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; CLINICAL TRIALS, PHASE II; HUMANS; OSTEOSARCOMA; RESEARCH DESIGN; RHABDOMYOSARCOMA;

EID: 0034848308     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200108000-00002     Document Type: Editorial

References (37)

1. Breitfeld PP, Lyden E, Raney RB, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 2001; 23 (4):225-33.
2. Ferguson WS, Harris MB, Goorin AM, et al. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group trial. J Pediatr Hematol Oncol 2001; 23 (6):340-8.
3. Horowitz ME, Etcubanas E, Christensen ML, et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 1988; 6:308-14.
4. Meyer WH, Houghton PJ, Horowitz ME, et al. Use of investigational drugs as initial therapy for childhood solid tumors. Hamatol Bluttransfus 1989; 32:141-8.
5. Castleberry RP, Cantor AB, Green AA, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1994; 12:1616-20.
6. Vietti T, Crist W, Ruby E, al. Topotecan window in patients with rhabdomyosarcoma (RMS): an IRSG study. Proc Am Soc Clin Oncol 1997;16:510a.
7. Sandler E, Lyden E, Ruymann F, et al. Efficacy of ifosfamide (IFOS) and doxorubicin (DOX) given as a phase II “window” in children with newly diagnosed metastatic rhabdomyosarcoma (RMS): a report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Proc Am Soc Clin Oncol 1999; 18:562a.
8. Meyer W, Breitfeld P, Lyden E, et al. The drug pair topotecan/cyclophosphamide is active in previously untreated rhabdomyosarcoma (RMS): a report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Proc Am Soc Clin Oncol 2000; 19:582a.
9. Chantada GL, Fandino A, Mato G, et al. Phase II window of idarubicin in children with extraocular retinoblastoma. J Clin Oncol 1999; 17:1847-50.
10. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 1995; 24:87-92.
11. Goorin AM, Gieser P, Ferguson W, et al. Successful phase II trial of etoposide and high dose ifosfamide in newly diagnosed metastatic osteosarcoma: a Pediatric Oncology Group trial (POG). Proc Am Soc Clin Oncol 1998; 17:535a.
12. Petrilli AS, Kechichian R, Broniscer A, et al. Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma. Med Pediatr Oncol 1999; 33:71-5.
13. Zoubek A, Kajtar P, Flucher-Wolfram B, et al. Response of untreated stage IV Wilms tumor to single dose carboplatin assessed by “up front” window therapy. Med Pediatr Oncol 1995; 25:8-11.
14. Razzouk BI, Heideman RL, Friedman HS, et al. A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer 1995; 75:2762-7.
15. McCowage GB, Friedman HS, Moghrabi A, et al. Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas. Med Pediatr Oncol 1998; 30:75-80.
16. Kadota RP, Kun LE, Langston JW, et al. Cyclophosphamide for the treatment of progressive low-grade astrocytoma: a Pediatric Oncology Group phase II Study. J Pediatr Hematol Oncol 1999; 21:198-202.
17. Beauchamp TL, Lukens JN, Sallan SE, et al. Phase II window studies in pediatric oncology: Meeting report. Cancer Therapy Evaluation Program, NCI; 1997. Available at: http://ctep.info.nih.gov/Policies/Phase2.htm.
18. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13:610-30.
19. Warrell Jr, RP Maslak P, Eardley A, et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994; 8:929-33.
20. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia [published erratum appears in N Engl J Med 1997;337:1639]. N Engl J Med 1997; 337:1021-8.
21. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111:273-9.
22. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
23. Nabholtz JM, North S, Smylie M, et al. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol 2000; 27(2S3):11-8.
24. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17:2341-54.
25. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17:1413-24.
26. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5:1191-8.
27. Grier H, Krailo M, Link M, et al. Improved outcome in nonmetastatic Ewing's sarcoma and PNET of bone with the addition of ifosfamide and etoposide to vincristine, Adriamycin, cyclophosphamide, and actinomycin: a Children's Cancer Group and Pediatric Oncology Group report. Proc Am Soc Clin Oncol 1994; 13:421a.
28. Sorensen JM, Vena DA, Fallavollita A, et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol 1997; 15:458-65.
29. Hocepied AM, Falkson CI, Falkson G. A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia. S Afr Med J 1996; 86:549-50.
30. Johnson S, Smith AG, Loffler H, et al. Multicenter prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347:1432-8.
31. Pappo A, Anderson J, Qualman S, et al. Second malignant neoplasms (SMN) in IRSG-IV: a preliminary report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Proc Am Soc Clin Oncol 2000; 19:584a.
32. Bokemeyer C, Kohrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with “good-risk” metastatic non-seminomatous germ cell tumors. Ann Oncol 1996; 7:1015-21.
33. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15:1844-52.
34. Bacci G, Mercuri M, Briccoli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 1997; 79:245-54.
35. Bacci G, Briccoli A, Mercuri M, et al. Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. J Chemother 1998; 10:69-76.
36. Kretschmar C, Kletzel M, Murray K, et al. Upfront phase II therapy with taxol and topotecan in untreated children (>365 days) with disseminated (INSS stage 4) neuroblastoma: a Pediatric Oncology Group Study [abstract]. Med Pediatr Oncol 1995; 25:243.
37. Zee B, Melnychuk D, Dancey J, et al. Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Stat 1999; 9:351-63.